Our top pick for
Building a portfolio
Endo International plc is a drug manufacturers-specialty & generic business based in the US. Endo International shares (ENDP) are listed on the NASDAQ and all prices are listed in US Dollars. Endo International employs 3,397 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.71 - $10.73|
|50-day moving average||$7.07|
|200-day moving average||$6.70|
|Wall St. target price||$7.70|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Endo International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Endo International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Endo International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Endo International shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Endo International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $790.8 million.
The EBITDA is a measure of a Endo International's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.9 billion|
|Operating margin TTM||23.82%|
|Gross profit TTM||$1.5 billion|
|Return on assets TTM||4.63%|
|Return on equity TTM||0%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
There are currently 19.6 million Endo International shares held short by investors – that's known as Endo International's "short interest". This figure is 7.4% up from 18.2 million last month.
There are a few different ways that this level of interest in shorting Endo International shares can be evaluated.
Endo International's "short interest ratio" (SIR) is the quantity of Endo International shares currently shorted divided by the average quantity of Endo International shares traded daily (recently around 3.2 million). Endo International's SIR currently stands at 6.15. In other words for every 100,000 Endo International shares traded daily on the market, roughly 6150 shares are currently held short.
However Endo International's short interest can also be evaluated against the total number of Endo International shares, or, against the total number of tradable Endo International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Endo International's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Endo International shares in existence, roughly 80 shares are currently held short) or 0.1205% of the tradable shares (for every 100,000 tradable Endo International shares, roughly 121 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Endo International.
Find out more about how you can short Endo International stock.
We're not expecting Endo International to pay a dividend over the next 12 months.
Over the last 12 months, Endo International's shares have ranged in value from as little as $2.71 up to $10.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Endo International's is 1.5565. This would suggest that Endo International's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.